6-Phosphogluconate dehydrogenase
Class of enzymes
From Wikipedia, the free encyclopedia
6-Phosphogluconate dehydrogenase (6PGD) is an enzyme in the pentose phosphate pathway. It forms ribulose 5-phosphate from 6-phosphogluconate:[2]
| Phosphogluconate dehydrogenase | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 6-phosphogluconate dehydrogenase dimer, Ovis aries | |||||||||
| Identifiers | |||||||||
| EC no. | 1.1.1.44 | ||||||||
| CAS no. | 9001-82-5 | ||||||||
| Databases | |||||||||
| BRENDA | enzyme data | ||||||||
| ExPASy | NiceZyme view | ||||||||
| KEGG | enzyme entry | ||||||||
| MetaCyc | metabolic pathway | ||||||||
| Rhea | reactions | ||||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||||
| Gene Ontology | AmiGO / QuickGO | ||||||||
| |||||||||
It is an oxidative carboxylase that catalyses the oxidative decarboxylation of 6-phosphogluconic acid into ribulose 5-phosphate in the presence of oxidised NAD+. This reaction is a component of the hexose mono-phosphate shunt and pentose phosphate pathways (PPP).[3][4] Prokaryotic and eukaryotic 6PGD are proteins of about 470 amino acids whose sequences are highly conserved.[5] The protein is a homodimer in which the monomers act independently:[4] each contains a large, mainly alpha-helical domain and a smaller beta-alpha-beta domain, containing a mixed parallel and anti-parallel 6-stranded beta sheet.[4] NADP is bound in a cleft in the small domain, the substrate binding in an adjacent pocket.[4]
Biotechnological significance
Recently, 6PGD was demonstrated to catalyze also the reverse reaction (i.e. reductive carboxylation) in vivo.[6] Experiments using Escherichia coli selection strains revealed that this reaction was efficient enough to support the formation of biomass based solely on CO2 and pentose sugars. In the future, this property could be exploited for synthetic carbon fixation routes.
Clinical significance
Mutations within the gene coding this enzyme result in 6-phosphogluconate dehydrogenase deficiency, an autosomal hereditary disease affecting the red blood cells.
As a possible drug target
6PGD is involved in cancer cell metabolism so 6PGD inhibitors have been sought.[7]
See also
- Parietin, a 6PGD inhibitor
- Phosphogluconate dehydrogenase (decarboxylating) an enzyme that catalyses the same reaction but uses the cofactor NADP+
